title: [Stereotactic body radiotherapy].
abstract: Stereotactic body radiotherapy(SBRT)is defined as the management and delivery of image-guided high-dose radiation therapy with tumor ablative intent within a short course of treatment. SBRT was more effective than 3D-CRT. In the phase II JCOG0403 trial for T1N0M0 non-small-cell lung cancer, the 3-year overall survival rate was 76% for operable patients and 59.9% for inoperable patients. Several authors reported the treatment results in various dose-fractionation schedules. However, the optimal dose, fractionation regimen, and the dose reference method are yet to be determined. Clinical trial s comparing SBRT and sublobar resection were planned but too few cases were enrolled to provide definitive evidence. SBRT for hepatocellular carcinoma(HCC) is a standard treatment option for patients who are ineligible for resection or radiofrequency ablation. A phase II trial for untreated non-metastatic primary HCC is ongoing in Japan which is expected to provide more supporting evidence.
authors.affiliation: Dept. of Radiation Oncology, Hiroshima University Hospital.
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Okabe
authors.forename: Tomoki
authors.initials: T
authors.lastname: Kimura
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Nagata
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000532:radiotherapy; D006801:Humans; D008113:Liver Neoplasms / Q000532:radiotherapy; D008175:Lung Neoplasms / Q000532:radiotherapy; D011829:Radiation Dosage; D016634:Radiosurgery / Q000379:methods*